$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2015 Q2 Form 10-Q Financial Statement

#000119312515178432 Filed on May 08, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $8.700M $18.50M $8.300M
YoY Change 19.18% 122.89% -55.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.60M $12.70M $8.900M
YoY Change 26.96% 42.7% 41.27%
% of Gross Profit
Research & Development $67.01M $58.04M $43.76M
YoY Change 50.0% 32.63% 97.29%
% of Gross Profit
Depreciation & Amortization $5.000M $3.690M $2.600M
YoY Change 72.41% 41.92% 22.24%
% of Gross Profit
Operating Expenses $81.63M $70.76M $277.3M
YoY Change 56.08% -74.49% 874.97%
Operating Profit -$72.94M -$52.22M -$269.1M
YoY Change 62.08% -80.59% 2644.43%
Interest Expense $1.600M $1.000M $300.0K
YoY Change 128.57% 233.33% 50.0%
% of Operating Profit
Other Income/Expense, Net $1.592M $1.014M $251.0K
YoY Change 158.44% 303.98% 9.61%
Pretax Income -$71.35M -$51.21M -$268.8M
YoY Change 60.74% -80.95% 2707.45%
Income Tax $400.0K -$400.0K -$17.90M
% Of Pretax Income
Net Earnings -$71.78M -$50.78M -$250.9M
YoY Change 62.87% -79.77% 2684.23%
Net Earnings / Revenue -825.09% -274.47% -3023.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$850.7K -$618.8K -$3.701M
COMMON SHARES
Basic Shares Outstanding 84.28M shares 83.76M shares 63.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $940.0M $967.0M $665.5M
YoY Change 55.29% 45.3% 181.97%
Cash & Equivalents $151.3M $306.6M $350.6M
Short-Term Investments $788.7M $660.4M $314.9M
Other Short-Term Assets $15.10M $13.20M $8.400M
YoY Change 46.6% 57.14% 140.0%
Inventory
Prepaid Expenses
Receivables $9.400M $10.10M $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.029B $1.090B $674.1M
YoY Change 54.73% 61.73% 180.73%
LONG-TERM ASSETS
Property, Plant & Equipment $25.17M $21.17M $15.73M
YoY Change 48.46% 34.55% -17.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $456.8M $483.8M $390.5M
YoY Change 30.29% 23.89% 83.76%
Other Assets $19.70M $33.70M
YoY Change
Total Long-Term Assets $501.6M $538.6M $406.2M
YoY Change 36.48% 32.58% 75.5%
TOTAL ASSETS
Total Short-Term Assets $1.029B $1.090B $674.1M
Total Long-Term Assets $501.6M $538.6M $406.2M
Total Assets $1.531B $1.629B $1.080B
YoY Change 48.24% 50.77% 129.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.72M $15.49M $5.037M
YoY Change 154.78% 207.44% 62.22%
Accrued Expenses $17.76M $14.43M $16.60M
YoY Change 12.51% -13.09% 82.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $66.60M $80.69M $83.83M
YoY Change 23.91% -3.74% 68.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $55.60M $51.60M $1.000M
YoY Change 5460.0% 5060.0% -99.09%
Total Long-Term Liabilities $55.60M $51.60M $1.000M
YoY Change 5460.0% 5060.0% -99.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $66.60M $80.69M $83.83M
Total Long-Term Liabilities $55.60M $51.60M $1.000M
Total Liabilities $122.2M $132.3M $125.3M
YoY Change 35.16% 5.55% -21.68%
SHAREHOLDERS EQUITY
Retained Earnings -$1.079B -$1.007B -$847.2M
YoY Change 21.09% 18.91% 64.17%
Common Stock $2.469B $2.452B $1.777B
YoY Change 36.29% 37.95% 120.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.409B $1.497B $955.0M
YoY Change
Total Liabilities & Shareholders Equity $1.531B $1.629B $1.080B
YoY Change 48.24% 50.77% 129.08%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$71.78M -$50.78M -$250.9M
YoY Change 62.87% -79.77% 2684.23%
Depreciation, Depletion And Amortization $5.000M $3.690M $2.600M
YoY Change 72.41% 41.92% 22.24%
Cash From Operating Activities -$55.40M -$26.30M -$41.70M
YoY Change 18.88% -36.93% 4194.54%
INVESTING ACTIVITIES
Capital Expenditures -$1.300M $2.110M $388.0K
YoY Change -27.78% 443.81% -78.43%
Acquisitions
YoY Change
Other Investing Activities -$105.7M -$339.2M -$354.4M
YoY Change -53.33% -4.29% 174.73%
Cash From Investing Activities -$107.0M -$341.3M -$379.8M
YoY Change -53.15% -10.14% 190.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $496.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.100M 599.0M 718.9M
YoY Change 39.22% -16.68% 303.4%
NET CHANGE
Cash From Operating Activities -55.40M -26.30M -41.70M
Cash From Investing Activities -107.0M -341.3M -379.8M
Cash From Financing Activities 7.100M 599.0M 718.9M
Net Change In Cash -155.3M 231.4M 297.4M
YoY Change -42.46% -22.19% 540.96%
FREE CASH FLOW
Cash From Operating Activities -$55.40M -$26.30M -$41.70M
Capital Expenditures -$1.300M $2.110M $388.0K
Free Cash Flow -$54.10M -$28.41M -$42.09M
YoY Change 20.76% -32.5% 1419.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
95.00
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
84282698 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
350589000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84214295 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84214295 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14427000
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
46566000
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1010000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
80693000
CY2015Q1 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
33667000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
842000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
52385000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
15486000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1007407000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2450690000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
1496510000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1628790000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14099000
CY2015Q1 us-gaap Liabilities
Liabilities
132280000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5021000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
185000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
306580000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21166000
CY2015Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
10107000
CY2015Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1144517000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13206000
CY2015Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
33667000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
528000
CY2015Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
483771000
CY2015Q1 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
99890000
CY2015Q1 us-gaap Assets
Assets
1628790000
CY2015Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
660403000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
1090186000
CY2015Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1144174000
CY2015Q1 alny Accrued Intraperiod Tax Allocation
AccruedIntraperiodTaxAllocation
2004000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53169000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77202753 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77202753 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1005000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42983000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95334000
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
31667000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
772000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
48763000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15111000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-956630000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1843362000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23680000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
936267000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1079595000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23871000
CY2014Q4 us-gaap Liabilities
Liabilities
143328000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5011000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75179000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21740000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
39937000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
807843000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9739000
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
31667000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1121000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
279821000
CY2014Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
94583000
CY2014Q4 us-gaap Assets
Assets
1079595000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
526929000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
746367000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
806750000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5447368 shares
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
496400000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21100000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-41675000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67786000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.70
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8573000 shares
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
487598000
CY2014Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4084000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4499000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-268813000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-269064000
CY2014Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
723037000
CY2014Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
8275000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-245630000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
251000
CY2014Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
388000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-157000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-250943000
CY2014Q1 us-gaap Investment Income Net
InvestmentIncomeNet
333000
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15703000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5313000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2600000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7845000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
277339000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43758000
CY2014Q1 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-17870000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
297420000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
718875000
CY2014Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
224656000
CY2014Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3773000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-379780000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8925000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1379000
CY2014Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11541000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
133206000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5591000
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
CY2015Q1 dei Trading Symbol
TradingSymbol
ALNY
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26255000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect&#xA0;the reported amounts of assets and liabilities and&#xA0;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&#xA0;the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82074000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-29830000
CY2015Q1 us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
0
CY2015Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
18537000
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001178670
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7805000 shares
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
507617000
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
288000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3179000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51208000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-52222000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47155000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
168687000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8236000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1014000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2110000
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-247000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-50777000
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1014000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3622000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3690000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6189000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
70759000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58035000
CY2015Q1 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-431000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
231401000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
89018000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
598984000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
496400000
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-8432000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-341328000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12724000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
750000
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
13566000
CY2015Q1 alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
CY2015Q1 alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D

Files In Submission

Name View Source Status
0001193125-15-178432-index-headers.html Edgar Link pending
0001193125-15-178432-index.html Edgar Link pending
0001193125-15-178432.txt Edgar Link pending
0001193125-15-178432-xbrl.zip Edgar Link pending
alny-20150331.xml Edgar Link completed
alny-20150331.xsd Edgar Link pending
alny-20150331_cal.xml Edgar Link unprocessable
alny-20150331_def.xml Edgar Link unprocessable
alny-20150331_lab.xml Edgar Link unprocessable
alny-20150331_pre.xml Edgar Link unprocessable
d896392d10q.htm Edgar Link pending
d896392dex101.htm Edgar Link pending
d896392dex102.htm Edgar Link pending
d896392dex103.htm Edgar Link pending
d896392dex311.htm Edgar Link pending
d896392dex312.htm Edgar Link pending
d896392dex321.htm Edgar Link pending
d896392dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g896392new.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending